Please assess the completion status of the following clinical trial:

Trial Title: The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older patients with CAP.~* Patients who were diagnosed as moderate in severity.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides.~* Hepatic dysfunction (AST, ALT, total bilirubin \> 3 times institutional normal).~* Severe renal dysfunction (creatinine clearance \< 30 ml/min).~* Patients who have a history of severe heart diseases (4th -degree of NYHA). Patients who have a congenital or sporadic long QT syndrome, or who are received the drugs with reported QT prolongation.~* Severe underlying disease.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Azithromycin switch therapy (switch from intravenous to oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).